Tag: Amgen targeted therapies

Home / Amgen targeted therapies

Categories

Sotorasib with panitumumab is approved by the USFDA for KRAS G12C-mutated colorectal cancer

On January 16, 2025, the Food and Drug Administration sanctioned the use of sotorasib (Lumakras, Amgen Inc.) in conjunction with panitumumab (Vectibix, Amgen Inc.) for adult patients diagnosed with KR...
amgen-targeted-therapies

Scan the code